POINT Biopharma Global (PNT) Stock Price, News & Analysis

Company Overview

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Key Stats

• Today's Range: N/A
• 50-Day Range: $12.45 to $14.23
• 52-Week Range: N/A
• Volume: 3.29 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $1.33 billion
• P/E Ratio: 13.89
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Hold

PNT Stock Analysis - Frequently Asked Questions

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. The business had revenue of $2.79 million for the quarter, compared to analyst estimates of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%.

What other stocks do shareholders of POINT Biopharma Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that POINT Biopharma Global investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Disc Medicine (IRON), Arista Networks (ANET), e.l.f. Beauty (ELF) and Builders FirstSource (BLDR).

Company Calendar

• Last Earnings: 11/13/2023
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PNT
• CUSIP: N/A
• CIK: 1811764
• Web: www.pointbiopharma.com
• Phone: 64-7812-2417
• Fax: N/A
• Employees: 129
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.50
• High Stock Price Target: $12.50
• Low Stock Price Target: $12.50
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.90
• Trailing P/E Ratio: 13.89
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $98.29 million
• Net Margins: 39.62%
• Pretax Margin: 52.16%
• Return on Equity: 21.10%
• Return on Assets: 18.28%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 9.14
• Quick Ratio: 9.14

Sales & Book Value

• Annual Sales: $226.58 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 13.31
• Book Value: $4.68 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 106,570,000
• Free Float: 89,518,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: N/A